Holen Sie sich die Stockscreener-App
3.18
2.91%
-0.08
Schlusskurs vom Vortag:
$3.26
Offen:
$3.29
24-Stunden-Volumen:
178.35K
Relative Volume:
0.49
Marktkapitalisierung:
$195.30M
Einnahmen:
$45.15M
Nettoeinkommen (Verlust:
$-39.23M
KGV:
-1.7387
EPS:
-1.829
Netto-Cashflow:
$-18.93M
1W Leistung:
+0.48%
1M Leistung:
-31.79%
6M Leistung:
-51.08%
1J Leistung:
-43.08%
1-Tages-Spanne:
$3.12
$3.39
1-Wochen-Bereich:
$3.02
$3.55
52-Wochen-Spanne:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Firmenname
Trisalus Life Sciences Inc
Sektor
Branche
Telefon
415 336 8917
Adresse
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
3.18 | 200.22M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
86.53 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.99 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.79 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.72 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.69 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Lake Street | Buy |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Eingeleitet | ROTH MKM | Buy |
| 2024-10-25 | Eingeleitet | Northland Capital | Outperform |
| 2024-09-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-30 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation - ACCESS Newswire
TLSI Q1 2026 Earnings: EPS Surprises Positively Despite No Revenue, Stock DeclinesGlobal Trading Community - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life - The National Law Review
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: EPS Surges Past Expectations, Yet Stock SlipsEBITDA Margin Trends - Newser
TLSI (TLSI) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Certain Stock Options of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
James Pallotta reports 5.2% stake in TriSalus Life Sciences (TLSI) - Stock Titan
38 startups join Innosphere life-sciences incubator - BizWest
Levi & Korsinsky Announces Investigation of Securities Claims Against TLSI (TLSI) - GlobeNewswire
TriSalus (TLSI) CCO reports 543-share tax-withholding sale, retains over 125K shares - Stock Titan
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud - Business Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock Price Today & Analysis - Gotrade
TLSI Insider Buying Surge: 5 Executives Purchase $1.3M in Stock - Meyka
TriSalus Life Sciences Director Purchased Shares Worth Over $1.5M - TradingView
TriSalus Life Sciences (TLSI) director buys 10,000 shares in open market - Stock Titan
Director Mats Wahlstrom boosts TriSalus (TLSI) stake with 60,000-share open-market buy - Stock Titan
TriSalus (TLSI) director and LLC add 610K shares in open-market buys - Stock Titan
TriSalus (TLSI) CEO Mary Szela adds 39,682 shares in open-market stock purchase - Stock Titan
TriSalus (TLSI) CFO adds 7,100 shares in open-market purchase - Stock Titan
Earnings call transcript: TriSalus Life Sciences Q1 2026 sees stock gain despite revenue dip By Investing.com - Investing.com Australia
Earnings call transcript: TriSalus Life Sciences Q1 2026 sees stock gain despite revenue dip - Investing.com UK
TLSI SHAREHOLDER INVESTIGATION: SueWallSt Investigates TLSI for Possible Securities Law Violations - PR Newswire
TriSalus Life Sciences Q1 earnings call highlights - MSN
TLSI Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of TLSI (TLSI) - Morningstar
TriSalus Stockholders Back Directors, Auditor and Pay Policies - The Globe and Mail
First Light, Mathew P. Arens disclose 5.37M TLSI shares (TLSI) - Stock Titan
TriSalus (TLSI) grants RSUs and stock options to director Kerry Hicks - Stock Titan
TriSalus (TLSI) director granted RSU and stock option awards - Stock Titan
TriSalus (TLSI) director receives RSU and stock option grants - Stock Titan
TriSalus (TLSI) director Matlin receives RSU and option grants for 2026 service - Stock Titan
TriSalus Life Sciences (TLSI) director granted RSUs and stock options in 2026 award - Stock Titan
TriSalus Life Sciences (TLSI) directors re-elected and pay plan backed in 2026 vote - Stock Titan
TriSalus (TLSI) Q1 2026 Earnings Transcript - AOL.com
Canaccord Genuity Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI) - The Globe and Mail
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results - Sahm
Dow Falls 200 Points; US Producer Prices Surge In April - Sahm
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Lake Street Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
TriSalus Life Sciences Bets Big Amid FDA Delay - TipRanks
TriSalus Life Sciences, Inc. Stock 12‑Month Price Target Cut to $8.8, Implies 93% Upside - TradingView
Earnings call transcript: TriSalus Life Sciences Q1 2026 revenue dips amid expansion By Investing.com - Investing.com India
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TriSalus Life Sciences Q1 Earnings Call Highlights - sharewise.com
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
TLSI: Landmark PEDD study and expanded sales force set stage for growth despite revised 2026 guidance - TradingView
TLSI: Landmark PEDD study and commercial expansion drive revised 2026 outlook and growth strategy - TradingView
TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript - Benzinga
Finanzdaten der Trisalus Life Sciences Inc-Aktie (TLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trisalus Life Sciences Inc-Aktie (TLSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):